Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $333.00

Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) had its price objective increased by Wells Fargo & Company from $287.00 to $333.00 in a report issued on Monday,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company's stock.

Several other equities research analysts have also commented on ALNY. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a report on Friday, March 21st. Wall Street Zen downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. JPMorgan Chase & Co. raised their target price on Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the stock an "overweight" rating in a report on Thursday, June 12th. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Finally, Stifel Nicolaus raised their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $340.00.

Alnylam Pharmaceuticals Stock Performance

ALNY stock traded up $6.32 during midday trading on Monday, reaching $328.38. The stock had a trading volume of 581,065 shares, compared to its average volume of 857,520. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $339.59. The stock has a market cap of $42.82 billion, a PE ratio of -156.62 and a beta of 0.23. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The firm has a fifty day simple moving average of $289.81 and a two-hundred day simple moving average of $264.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same quarter in the prior year, the company earned ($0.16) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% on a year-over-year basis. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the sale, the chief executive officer directly owned 48,948 shares of the company's stock, valued at $14,899,281.72. The trade was a 39.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AG2R LA Mondiale Gestion D Actifs purchased a new position in shares of Alnylam Pharmaceuticals in the first quarter worth about $1,573,000. Swedbank AB grew its position in shares of Alnylam Pharmaceuticals by 8.0% in the first quarter. Swedbank AB now owns 59,993 shares of the biopharmaceutical company's stock valued at $16,199,000 after purchasing an additional 4,461 shares in the last quarter. Strs Ohio acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $7,781,000. Geneos Wealth Management Inc. lifted its position in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 175 shares in the last quarter. Finally, IFM Investors Pty Ltd boosted its stake in Alnylam Pharmaceuticals by 0.6% during the first quarter. IFM Investors Pty Ltd now owns 23,850 shares of the biopharmaceutical company's stock worth $6,440,000 after buying an additional 150 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.